Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma

Resistance to gemcitabine is the main challenge of chemotherapy for pancreatic ductal adenocarcinoma (PDAC). Hence, the development of a response signature to gemcitabine is essential for precision therapy of PDAC. However, existing quantitative signatures of gemcitabine are susceptible to batch eff...

Full description

Bibliographic Details
Main Authors: Kaidong Liu, Yiding Geng, Linzhu Wang, Huanhuan Xu, Min Zou, Yawei Li, Zhangxiang Zhao, Tingting Chen, Fengyan Xu, Liang Sun, Shuliang Wu, Yunyan Gu
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:Molecular Oncology
Subjects:
drug response signature
gemcitabine
immunity
pancreatic ductal adenocarcinoma
single cell
Online Access:https://doi.org/10.1002/1878-0261.13279

Internet

https://doi.org/10.1002/1878-0261.13279

Similar Items